in process …


Something bad happened. You should try to fix …


The action is completed.

5. Greenfield S, Blanco DM, Elashoff RM,

Over the past decade, new cytotoxic and biologic therapies beyond the old standard-of-care, biomodulated fluorouracil (5-FU), have become available for the treatment of metastatic colorectal cancer (mCRC). The introductions of irinotecan (Camptosar), oxaliplatin (Eloxatin), and bevacizumab (Avastin) have prolonged survival, but the optimal use of these new therapies remains to be determined. Issues remain regarding management of toxicities, treatment of elderly patients or those with poor performance status

Thus, we analyzed data from the 2001 Behavioral Risk Factor Surveillance System (BRFSS), a large, nationally representative telephone survey, to address some of the limitations of earlier studies. We sought to determine whether, after adjusting for potential confounders including health status, self-reported rates of completion of evidence-based colorectal cancer screening decrease between the ages of 50 and 80 years, as would be predicted based on ageism bias. We also compared age-related patterns of color

Carney, Gemma M. and Gray, Mia 2015. Unmasking the ‘elderly mystique’: Why it is time to make the personal political in research. , Vol. 35, p. 123.

Many comorbidity indices rely on medical records [e.g., Charlson Index (), Cumulative Illness Scale (), Index of Coexistent Diseases (), and Kaplan–Feinstein Index ()]. An important advantage of medical records is the good correspondence between diagnosed conditions and the disease entities ordinarily included in comorbidity indices. Another important advantage is that medical records reflect the information available to clinicians treating the patient/study participant. As comorbidity indices are o

Related links


cancer medical screening line index